WPI 900 (Glipizide extended release 2.5 mg)
Pill with imprint WPI 900 is Yellow, Round and has been identified as Glipizide extended release 2.5 mg. It is supplied by Watson Pharmaceuticals.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 2.5 mg is not a controlled substance under the Controlled Substance Act (CSA).
Images for WPI 900
- WPI 900
- 2.5 mg
- Prescription only
- Drug Class:
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Watson Pharmaceuticals
- Inactive Ingredients:
- acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
methacrylic acid - methyl methacrylate copolymer (1:1)
FD&C Yellow No. 6
Note: Inactive ingredients may vary.
Other Labelers / Repackagers:
|NDC Code||Labeler / Repackager|
|68084-0295||Amerisource Health Services|
More about glipizide
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 43 Reviews – Add your own review/rating
- Drug class: sulfonylureas
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.